{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:47:57Z","timestamp":1789548477263,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":280,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK076169"],"award-info":[{"award-number":["DK076169"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.crphar.2024.100203","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:36:53Z","timestamp":1728553013000},"page":"100203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Exacerbation of atherosclerosis, hyperlipidemia and inflammation by MK886, an inhibitor of leukotriene biosynthesis, in obese and diabetic mice"],"prefix":"10.1016","volume":"7","author":[{"given":"Katherine","family":"Keever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-5817","authenticated-orcid":false,"given":"Bardia","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.crphar.2024.100203_bib1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/labinvest.2014.80","article-title":"Effects of CP-900691, a novel peroxisome proliferator-activated receptor alpha, agonist on diabetic nephropathy in the BTBR ob\/ob mouse","volume":"94","author":"Askari","year":"2014","journal-title":"Lab. Invest."},{"key":"10.1016\/j.crphar.2024.100203_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11883-008-0038-7","article-title":"Inflammatory signaling through leukotriene receptors in atherosclerosis","volume":"10","author":"B\u00e4ck","year":"2008","journal-title":"Curr. Atherosclerosis Rep."},{"issue":"27","key":"10.1016\/j.crphar.2024.100203_bib3","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.2174\/138161209789058020","article-title":"Inhibitors of the 5-lipoxygenase pathway in atherosclerosis","volume":"15","author":"B\u00e4ck","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"issue":"7","key":"10.1016\/j.crphar.2024.100203_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000264498.60702.0d","article-title":"5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation","volume":"100","author":"B\u00e4ck","year":"2007","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-kappaB, inflammation, and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.crphar.2024.100203_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.tcm.2021.02.001","article-title":"Role of inflammatory cytokines in genesis and treatment of atherosclerosis","volume":"32","author":"Biros","year":"2022","journal-title":"Trends Cardiovasc. Med."},{"issue":"1\u20132","key":"10.1016\/j.crphar.2024.100203_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.prostaglandins.2007.03.005","article-title":"Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice","volume":"84","author":"Cao","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"5","key":"10.1016\/j.crphar.2024.100203_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000106485","article-title":"Peroxisome proliferator-activated receptor-alpha deficiency protects aged mice from insulin resistance induced by high-fat diet","volume":"27","author":"Cha","year":"2007","journal-title":"Am. J. Nephrol."},{"issue":"6","key":"10.1016\/j.crphar.2024.100203_bib9","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1161\/ATVBAHA.121.316066","article-title":"Sexually dimorphic relationships among Saa3 (serum amyloid A3), inflammation, and cholesterol metabolism modulate atherosclerosis in mice","volume":"41","author":"Chait","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2010.05.003","article-title":"Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice","volume":"212","author":"Choi","year":"2010","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.crphar.2024.100203_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3858\/emm.2011.43.8.053","article-title":"5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion","volume":"43","author":"Choi","year":"2011","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.crphar.2024.100203_bib12","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.1201272","article-title":"Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat","volume":"189","author":"Claria","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.crphar.2024.100203_bib13","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3389\/fimmu.2017.01400","article-title":"Pro-resolving mediators in regulating and conferring macrophage function","volume":"8","author":"Dalli","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp038190","article-title":"From asthma to atherosclerosis \u2014 5-lipoxygenase, leukotrienes, and inflammation","volume":"350","author":"De Caterina","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.crphar.2024.100203_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071738","article-title":"Dietary fatty acids at the crossroad between obesity and colorectal cancer: fine regulators of adipose tissue homeostasis and immune response","volume":"10","author":"Del Corno","year":"2021","journal-title":"Cells"},{"issue":"6255","key":"10.1016\/j.crphar.2024.100203_bib16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/343282a0","article-title":"Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis","volume":"373","author":"Dixon","year":"1990","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.crphar.2024.100203_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1615\/CritRevImmunol.v32.i4.40","article-title":"Immune functions of serum amyloid A","volume":"32","author":"Eklund","year":"2012","journal-title":"Critical Reviews\u2122 in Immunology"},{"issue":"8","key":"10.1016\/j.crphar.2024.100203_bib18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2337\/db16-0040","article-title":"ALOX5AP overexpression in adipose tissue leads to LXA4 production and protection against diet-induced obesity and insulin resistance","volume":"65","author":"Elias","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues","volume":"226","author":"Folch","year":"1957","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.crphar.2024.100203_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12859","article-title":"An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques","volume":"7","author":"Fredman","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.crphar.2024.100203_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/ajrccm\/147.4.839","article-title":"Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses","volume":"147","author":"Friedman","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"issue":"8","key":"10.1016\/j.crphar.2024.100203_bib21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrd1796","article-title":"Leukotriene modifiers as potential therapeutics for cardiovascular disease","volume":"4","author":"Funk","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.crphar.2024.100203_bib22","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/ATVBAHA.116.306874","article-title":"Do the Apoe-\/- and Ldlr-\/- mice yield the same insight on atherogenesis?","volume":"36","author":"Getz","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.crphar.2024.100203_bib23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1139\/y89-073","article-title":"L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindoI-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor","volume":"67","author":"Gillard","year":"1989","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"12","key":"10.1016\/j.crphar.2024.100203_bib24","doi-asserted-by":"crossref","DOI":"10.2337\/diabetes.50.12.2809","article-title":"PPAR-alpha\u2013Null mice are protected from high-fat diet\u2013induced insulin resistance","volume":"50","author":"Guerre-Millo","year":"2001","journal-title":"Diabetes"},{"issue":"35","key":"10.1016\/j.crphar.2024.100203_bib25","doi-asserted-by":"crossref","first-page":"31789","DOI":"10.1074\/jbc.M204450200","article-title":"Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors","volume":"277","author":"Gugliucci","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.crphar.2024.100203_bib26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1152\/physrev.00004.2012","article-title":"Molecular biology of atherosclerosis","volume":"93","author":"Hopkins","year":"2013","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.crphar.2024.100203_bib27","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.4049\/jimmunol.0901355","article-title":"5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity","volume":"184","author":"Horrillo","year":"2010","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.crphar.2024.100203_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.crphar.2024.100203_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2007.02.012","article-title":"5-Lipoxygenase inhibitor MK-886 increases GluR1 phosphorylation in neuronal cultures in vitro and in the mouse cortex in vivo","volume":"1147","author":"Imbesi","year":"2007","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.crphar.2024.100203_bib30","first-page":"583","article-title":"Bay X 1005 attenuates atherosclerosis in apoe\/LDLR - double knockout mice","volume":"58","author":"Jawie\u00f1","year":"2007","journal-title":"J. Physiol. Pharmacol."},{"issue":"3","key":"10.1016\/j.crphar.2024.100203_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2362.2006.01606.x","article-title":"Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE\/LDLR-double knockout mice","volume":"36","author":"Jawien","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.crphar.2024.100203_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.ijo.0803147","article-title":"ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance","volume":"30","author":"Kaaman","year":"2006","journal-title":"Int. J. Obes."},{"issue":"6","key":"10.1016\/j.crphar.2024.100203_bib33","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1172\/JCI26498","article-title":"MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity","volume":"116","author":"Kanda","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.crphar.2024.100203_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/mol.108.051656","article-title":"Molecular characterization of novel and selective peroxisome proliferator-activated receptor \u03b1 agonists with robust hypolipidemic activity in vivo","volume":"75","author":"Kane","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"19","key":"10.1016\/j.crphar.2024.100203_bib35","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease: the framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.crphar.2024.100203_bib36","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1042\/bj3560899","article-title":"Inhibition of peroxisome-proliferator-activated receptor (PPAR)\u03b1 by MK886","volume":"356","author":"Kehrer","year":"2001","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.crphar.2024.100203_bib37","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1096\/fj.15-275487","article-title":"Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein","volume":"29","author":"Lehmann","year":"2015","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.crphar.2024.100203_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/01.CIR.0000136819.93989.E1","article-title":"Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice","volume":"110","author":"Lewis","year":"2004","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.crphar.2024.100203_bib39","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.crphar.2024.100203_bib40","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1194\/jlr.M800101-JLR200","article-title":"Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice","volume":"49","author":"Lopez-Parra","year":"2008","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib41","first-page":"30","article-title":"The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis","volume":"1736","author":"Lotzer","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.crphar.2024.100203_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0561s58","article-title":"Overview of animal models of obesity","author":"Lutz","year":"2012","journal-title":"Curr. Protoc. Pharmacol."},{"issue":"7","key":"10.1016\/j.crphar.2024.100203_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/biom11070937","article-title":"The role of resolvins, protectins and marensins in non-alcoholic fatty liver disease (NAFLD)","volume":"11","author":"Maciejewska-Markiewicz","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.crphar.2024.100203_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.RES.0000028008.99774.7F","article-title":"Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice","volume":"91","author":"Mehrabian","year":"2002","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.119.264143","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"372","author":"Michel","year":"2020","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6255","key":"10.1016\/j.crphar.2024.100203_bib46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/343278a0","article-title":"Identification and isolation of a membrane protein necessary for leukotriene production","volume":"343","author":"Miller","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.93","article-title":"Common misconceptions about data analysis and statistics","volume":"3","author":"Motulsky","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"10.1016\/j.crphar.2024.100203_bib48","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.crphar.2024.100203_bib49","article-title":"Eicosanoids: atherosclerosis and cardiometabolic health","volume":"19","author":"Piper","year":"2020","journal-title":"J Clin Transl Endocrinol"},{"issue":"10","key":"10.1016\/j.crphar.2024.100203_bib50","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.4049\/jimmunol.1501261","article-title":"Prolonged intake of dietary lipids alters membrane structure and T cell responses in LDLr-\/- mice","volume":"196","author":"Pollock","year":"2016","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbrc.2010.02.173","article-title":"Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis","volume":"396","author":"Radmark","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.crphar.2024.100203_bib52","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2174\/138945010791320881","article-title":"Leukotrienes and atherosclerosis","volume":"11","author":"Riccioni","year":"2010","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0889-857X(03)00117-0","article-title":"Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics","volume":"30","author":"Serhan","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"10.1016\/j.crphar.2024.100203_bib54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000312669","article-title":"Cysteinyl leukotrienes and their receptors: molecular and functional characteristics","volume":"85","author":"Singh","year":"2010","journal-title":"Pharmacology"},{"issue":"6","key":"10.1016\/j.crphar.2024.100203_bib55","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1210\/en.2007-0014","article-title":"Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation","volume":"148","author":"Stienstra","year":"2007","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.crphar.2024.100203_bib56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/ATVBAHA.107.157685","article-title":"Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice","volume":"28","author":"Subramanian","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.crphar.2024.100203_bib57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/diab.37.9.1163","article-title":"Diet-nduced type II diabetes in C57bl\/6J mice","volume":"37","author":"Surwit","year":"1988","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.crphar.2024.100203_bib58","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.4049\/jimmunol.1100225","article-title":"Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype","volume":"187","author":"Titos","year":"2011","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.crphar.2024.100203_bib59","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.116.309492","article-title":"Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice","volume":"119","author":"Viola","year":"2016","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.crphar.2024.100203_bib60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1172\/JCI24335","article-title":"CCR2 modulates inflammatory and metabolic effects of high-fat feeding","volume":"116","author":"Weisberg","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.crphar.2024.100203_bib61","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.crphar.2024.100203_bib62","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.crphar.2024.100203_bib63","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s00125-011-2055-2","article-title":"Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice","volume":"54","author":"Yoon","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.crphar.2024.100203_bib64","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2019","journal-title":"Front. Physiol."},{"issue":"20","key":"10.1016\/j.crphar.2024.100203_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011128","article-title":"The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease","volume":"22","author":"Ziolkowska","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257124000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257124000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:34:49Z","timestamp":1752838489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257124000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":66,"alternative-id":["S2590257124000300"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2024.100203","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exacerbation of atherosclerosis, hyperlipidemia and inflammation by MK886, an inhibitor of leukotriene biosynthesis, in obese and diabetic mice","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2024.100203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100203"}}